Incomplete inhibition of platelet function as assessed by the platelet function analyzer (PFA-100) identifies a subset of cardiovascular patients with high residual platelet response while on aspirin

References

• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71–86
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849–1860
   PubMed Web of Science ®Google Scholar
• Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373–2383
   PubMed Web of Science ®Google Scholar
• Cattaneo M. Resistance to antiplatelet drugs: Molecular mechanisms and laboratory detection. J Thromb Haemost 2007; 5: 230–237
   PubMed Web of Science ®Google Scholar
• Crescente M, Di Castelnuovo A, Iacoviello L, Vermylen J, Cerletti C, de Gaetano G. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost 2008; 99: 14–26
   PubMed Web of Science ®Google Scholar
• de Gaetano G, Crescente M, Cerletti C. Current concepts about inhibition of platelet aggregation. Platelets 2008; 19: 565–570
   PubMed Web of Science ®Google Scholar
• Harrison P, Keeling D. Laboratory monitoring of antiplatelet therapy. In: Gresele P, Fuster V, Lopez JA, Page CP, Vermylen J, eds. Platelets in Hematologic and Cardiovascular Disorders. A Clinical Handbook. Cambridge University Press 2008: 386–407.
   Google Scholar
• Cattaneo M. Laboratory detection of “aspirin resistance”: What test should we use (if any)?. Eur Heart J 2007; 28: 1702–1708
   Google Scholar
• Patrono C, Rocca B. Aspirin: Promise and resistance in the new millennium. Arterioscler Thromb Vasc Biol 2008; 28: 25–32
   PubMed Web of Science ®Google Scholar
• Hovens MM, Snoep JD, Eikenboom JC, van der Bom JG, Mertens BJ, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: A systematic review. Am Heart J 2007; 153: 175–181
   PubMed Web of Science ®Google Scholar
• Lordkipanidzé M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28: 1702–1708
   PubMed Web of Science ®Google Scholar
• Patrono C. Aspirin resistance: Definition, mechanisms and clinical read-outs. J Thromb Haemost 2003; 1: 1710–1713
   PubMed Web of Science ®Google Scholar
• Cattaneo M. Aspirin and clopidogrel: Efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004; 24: 1980–1987
   PubMed Web of Science ®Google Scholar
• Crescente M, Di Castelnuovo A, Iacoviello L, de Gaetano G, Cerletti C. PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: A meta-analysis of 19 studies comprising 3,003 patients. Thromb Haemost 2008; 99: 1129–1131
   PubMedGoogle Scholar
• Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: A systematic review and meta-analysis. Arch Intern Med 2007; 167: 1593–1599
   PubMed Web of Science ®Google Scholar
• Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: Systematic review and meta-analysis. BMJ 2008; 36: 195–198
   Google Scholar
• Reny JL, de Moerloose P, Dauzat M, Fontana P. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: A systematic review and meta-analysis. J Thromb Haemost 2008; 6: 444–450
   PubMed Web of Science ®Google Scholar
• Frelinger AL, 3rd, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, Michelson AD. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 2009; 120: 2586–2596
   PubMed Web of Science ®Google Scholar
• Gianetti J, Parri MS, Sbrana S, Paoli F, Maffei S, Paradossi U, et al. Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: A 6 months prospective study. Thromb Res 2006; 118: 487–493
   PubMed Web of Science ®Google Scholar
• Campo G, Valgimigli M, Gemmati D, Percoco G, Tognazzo S, Cicchitelli G, et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: Insights into the STRATEGY Study. J Am Coll Cardiol 2006; 48: 2178–185
   PubMed Web of Science ®Google Scholar
• Feuring M, Wehling M, Ruf A, Schultz A. Circadian variation of platelet function measured with the PFA-100. Platelets 2009; 20: 466–470
   PubMed Web of Science ®Google Scholar
• Gresele P, Catalano M, Giammarresi C, Volpato R, Termini R, Ciabattoni G, et al. Platelet activation markers in patients with peripheral arterial disease–a prospective comparison of different platelet function tests. Thromb Haemost 1997; 78: 1434–1437
   PubMed Web of Science ®Google Scholar
• Giannini S, Mezzasoma AM, Leone M, Gresele P. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry. Haematologica 2007; 92: 1647–1654
   PubMed Web of Science ®Google Scholar
• Gouya G, Jilma B, Niel M, Eichelberger B, Wolzt M, Panzer S. Cross validation of aspirin effect in healthy individuals by Impact-R and PFA-100: A double blind randomized placebo controlled trial. Platelets 2009; 20: 171–176
   PubMed Web of Science ®Google Scholar
• Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 2000; 83: 316–321
   PubMed Web of Science ®Google Scholar
• Harrison P, Segal H, Silver L, Syed A, Cuthbertson FC, Rothwell PM. Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests. Platelets 2008; 19: 119–124
   PubMed Web of Science ®Google Scholar
• Corazzi T, Leone M, Maucci R, Corazzi L, Gresele P. Direct and irreversible inhibition of cyclooxygenase-1 (COX-1) by nitroaspirin (NCX 4016). J Pharmacol Exp Ther 2005; 315: 1331–1337
   PubMedGoogle Scholar
• Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230–235
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, et al. Evaluation of dose-related effects of aspirin on platelet function: Results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007; 115: 3156–3164
   PubMed Web of Science ®Google Scholar
• Leone M, Mezzasoma AM, Davì G, Gresele P. Detection of a critical degree of platelet TxA2-production inhibition by the PFA100 in aspirin-treated subjects: Possible relevance for the monitoring of aspirin resistance. J Thromb Haemost 2005; 3: P0964
   Google Scholar
• Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK. Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4: 312–319
   PubMed Web of Science ®Google Scholar
• Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006; 37: 2153–2158
   PubMed Web of Science ®Google Scholar
• Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: Implications for aspirin “resistance”. J Am Coll Cardiol 2009; 53: 667–677
   PubMed Web of Science ®Google Scholar
• Pignatelli P, Di Santo S, Barillà F, Gaudio C, Violi F. Multiple anti-atherosclerotic treatments impair aspirin compliance: Effects on aspirin resistance. J Thromb Haemost 2008; 6: 1832–1834
   Google Scholar
• Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005; 46: 1705–1709
   PubMed Web of Science ®Google Scholar
• Reiter RA, Mayr F, Blazicek H, Galehr E, Jilma-Stohlawetz P, Domanovits H, Jilma B. Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood 2003; 102: 4594–4599
   PubMed Web of Science ®Google Scholar
• Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G, Brizard A. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002; 107: 45–49
   PubMed Web of Science ®Google Scholar
• Godeneche G, Sorel N, Ragot S, Chomel JC, Neau JP, Macchi L. Stroke and aspirin non-responder patients: Relation with hypertension and platelet response to adenosine diphosphate. Platelets 2009; 20: 471–477
   PubMed Web of Science ®Google Scholar
• Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: Implications for therapy with platelet inhibitory drugs. Blood 1987; 69: 180–186
   PubMed Web of Science ®Google Scholar
• Di Minno G, Silver MJ, Murphy S. Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood 1983; 61: 1081–1085
   PubMed Web of Science ®Google Scholar
• Pulcinelli FM, Riondino S, Celestini A, Pignatelli P, Trifirò E, Di Renzo L, Violi F. Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin. J Thromb Haemost 2005; 3: 2784–2789
   Google Scholar
• Minuz P, Gaino S, Zuliani V, Tommasoli RM, Benati D, Ortolani R, et al. Functional role of p38 mitogen activated protein kinase in platelet activation induced by a thromboxane A2 analogue and by 8-iso-prostaglandin F2alpha. Thromb Haemost 2002; 87: 888–898
   PubMed Web of Science ®Google Scholar
• Minuz P, Fumagalli L, Gaino S, Tommasoli RM, Degan M, Cavallini C, et al. Rapid stimulation of tyrosine phoshorylation signals downstream of G-protein-coupled receptors for thromboxane A2 in human platelets. Biochem J 2006; 400: 127–134
   PubMed Web of Science ®Google Scholar
• Bach J, Kammerer I, Isgro F, Haubelt H, Vogt A, Saggau W, Hellstern P. The impact of intravenous aspirin administration on platelet aspirin resistance after on-pump coronary artery bypass surgery. Platelets 2009; 20: 150–157
   PubMed Web of Science ®Google Scholar
• Fuchs I, Spiel AO, Frossard M, Derhaschnig U, Riedmüller E, Jilma B. Platelet hyperfunction is decreased by additional aspirin loading in patients presenting with myocardial infarction on daily aspirin therapy. Crit Care Med 2010; 38: 1423–1429
   PubMed Web of Science ®Google Scholar
• Brambilla M, Parolari A, Camera M, Colli S, Eligini S, Centenaro C, et al. Effect of two doses of aspirin on thromboxane biosynthesis and platelet function in patients undergoing coronary surgery. Thromb Haemost 2010; 103: 516–524
   PubMed Web of Science ®Google Scholar
• de Gaetano G, Cerletti C. Platelet function, antiplatelet therapy and clinical outcomes: To test or not to test?. J Thromb Haemost 2007; 5: 1835–1838
   PubMedGoogle Scholar
• Santos MT, Valles J, Lago A, Tembl J, Sánchez E, Moscardo A, Cosin J. Residual platelet thromboxane A2 and prothrombotic effects of erythrocytes are important determinants of aspirin resistance in patients with vascular disease. J Thromb Haemost 2008; 6: 615–621
   PubMed Web of Science ®Google Scholar
• Momi S, Falcinelli E, Giannini S, Ruggeri L, Cecchetti L, Corazzi T, et al. Loss of matrix metalloproteinase-2 (MMP-2) in platelets reduces arterial thrombosis in vivo. J Exp Med 2009; 206: 2365–2379
   PubMed Web of Science ®Google Scholar
• Gresele P, Falcinelli E, Momi S. Potentiation and priming of platelet activation: A potential target or antiplatelet therapy. Trends Pharmacol Sci 2008; 29: 352–360
   PubMed Web of Science ®Google Scholar
• Frelinger AL, Li Y, Linden MD, Tarnow I, Barnard MR, Fox ML, Michelson AD. Aspirin ‘resistance’: Role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost 2008; 6: 2035–2044
   PubMedGoogle Scholar
• Faraday N, Yanek LR, Mathias R, Herrera-Galeano JE, Vaidya D, Moy TF, et al. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 2007; 115: 2490–2496
   PubMed Web of Science ®Google Scholar